الفهرس 
• CXCL9 Role in Different Diseases and in VitiligoOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Background: CXCL 9 is a chemokine of Th1 which plays a significant role in the development of vitiligo. NB-UVB is an effective modality for treatment of vitiligo.
Objective: To finding whether NB-UVB can affect serum and tissue CXCL9 level or not.
Patients and Methods: The present study included 20 patients suffering from non-segmental vitiligo and 20 age- and sex- matched healthy controls, their age ranged from 18 to 65 years old, they were recruited from the outpatient clinic of Dermatology and Andrology Department in Ain Shams University Hospital during the period from May 2019 till December 2019.
Results: We evaluated disease severity by assessment of body surface area (BSA) of vitiligo disease in patients with calculation of VES score before NB-UVB and to evaluate patient improvement after treatment with NB-UVB we recalculated VES score after NB-UVB and calculated VES plus score. There was significant decrease in the surface area of the disease after treatment with NB-UVB than before.
Conclusion: The present study provides clinical data to support the role of CXCL9 in vitiligo particularly during the activity of the disease. Also our findings draw our attention to CXCL9 not only as a marker of disease activity, but also potentially as a marker of treatment response. So, targeting the IFN-γ-chemokine axis might be an effective treatment strategy.